{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T12:54:38Z","timestamp":1795006478582,"version":"4.9.1"},"reference-count":86,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Emerging Microbes &amp; Infections"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/22221751.2026.2686471","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T09:08:52Z","timestamp":1780909732000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic approaches against dengue virus: current status of vaccines, antivirals, and monoclonal antibodies"],"prefix":"10.1080","volume":"15","author":[{"given":"Hawa Sophia","family":"Bouzidi","sequence":"first","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (Aix-Marseille Universit\u00e9, Universit\u00e0 di Corsica, IRD 190, Inserm 1207, IRBA)","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"De Lamballerie","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (Aix-Marseille Universit\u00e9, Universit\u00e0 di Corsica, IRD 190, Inserm 1207, IRBA)","place":["Marseille, France"]},{"name":"Centre National de R\u00e9f\u00e9rence des Arbovirus, Inserm-IRBA","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4734-2249","authenticated-orcid":false,"given":"Franck","family":"Touret","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus \u00c9mergents (Aix-Marseille Universit\u00e9, Universit\u00e0 di Corsica, IRD 190, Inserm 1207, IRBA)","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,21]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12060"},{"key":"e_1_3_3_3_1","unstructured":"Dengue worldwide overview. 2025. [accessed 2025 Aug 29]. Available from: https:\/\/www.ecdc.europa.eu\/en\/dengue-monthly."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2024.105710"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002055"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2010.08.007"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00118-14"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01653"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-024-01030-9"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2021-0791"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6836"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2008.06.028"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-022-00870-5"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1600999"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-021-00908-2"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.18-0309"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01067-9"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1989.40.444"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03007"},{"key":"e_1_3_3_20_1","first-page":"2025.08.11.2533","article-title":"Longitudinal antibody profiling after dengue reveals distinct dynamics by antibody specificity over 18 months","author":"Bos S","year":"2025","unstructured":"Bos S et al. Longitudinal antibody profiling after dengue reveals distinct dynamics by antibody specificity over 18 months. medRxiv. 2025:2025.08.11.25333449.","journal-title":"medRxiv"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/2051013613507862"},{"key":"e_1_3_3_22_1","unstructured":"Vaccins et vaccination\u202f: Dengue. [accessed 2026 Apr 23]. Available from: https:\/\/www.who.int\/fr\/news-room\/questions-and-answers\/item\/dengue-vaccines."},{"key":"e_1_3_3_23_1","unstructured":"Update by SAGE on the use of the first licenced dengue vaccine April 2018 - Global Dengue & Aedes-Transmitted Diseases Consortium (GDAC). 2013. [accessed 2026 Jan 29]. Available from: https:\/\/gdac-dengue.org\/news-events\/update-by-sage-on-the-use-of-the-first-licenced-dengue-vaccine-april-2018\/."},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7006a1"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.09.063"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100777"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab288"},{"key":"e_1_3_3_28_1","unstructured":"Dengvaxia | European Medicines Agency (EMA). 2018. [accessed 2026 May 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dengvaxia."},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13050532"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01778"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03771-y"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa761"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(23)00522-3"},{"key":"e_1_3_3_34_1","unstructured":"Editor AS Senior. Takeda\u2019s Phase III TIDES Trial confirms long-term efficacy and safety of Qdenga Dengue Vaccine | Applied Clinical Trials Online. 2026. [accessed 2026 Jan 29]. Available from: https:\/\/www.appliedclinicaltrialsonline.com\/view\/takeda-tides-trial-confirms-long-term-efficacy-safety-qdenga-dengue-vaccine."},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI173328"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00520-0"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00376-1"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301790"},{"key":"e_1_3_3_39_1","unstructured":"MSD Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate. MSD Singapore. [accessed 2025 Nov 17]. Available from: https:\/\/www.msd-singapore.com\/news\/msd-initiates-phase-3-study-evaluating-dengue-vaccine-candidate\/."},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2046960"},{"key":"e_1_3_3_41_1","unstructured":"Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENV\u039430 [Live Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181-002). MedPath. 2025. [accessed 2025 Nov 17]. Available from: https:\/\/trial.medpath.com\/clinical-trial\/c0e366486a3a61b5\/nct05710224-phase-2-clinical-study-v181-dengue-vaccine."},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2022.100142"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.16-0634"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa603"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1546523"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-0416"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02482-20"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virs.2022.07.003"},{"key":"e_1_3_3_49_1","doi-asserted-by":"crossref","first-page":"e00239","DOI":"10.1128\/jvi.00239-24","article-title":"A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates","volume":"98","author":"Thoresen D","year":"2024","unstructured":"Thoresen D, et al. A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates. J Virol. 2024;98:e00239\u201324.","journal-title":"J Virol"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009664"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009606"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis470"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06612-2"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042022"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M400460200"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(90)90029-7"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.04.012"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0907010106"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00988-21"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01615-23"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03990-6"},{"key":"e_1_3_3_62_1","unstructured":"The antiviral JNJ-A07 significantly reduces dengue virus transmission by Aedes aegypti mosquitoes when delivered via blood-feeding | Science Advances. [accessed 2026 Apr 23]. Available from: https:\/\/www.science.org\/doi\/10.1126sciadv.adr8338."},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05790-6"},{"issue":"77","key":"e_1_3_3_64_1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/cid\/ciad284","article-title":"Safety, tolerability, and pharmacokinetics of JNJ-1802, a Pan-serotype dengue direct antiviral small molecule, in a phase 1, double-blind, randomized, dose-escalation study in healthy volunteers","volume":"2023","author":"Ackaert O","year":"2023","unstructured":"Ackaert O, et al. Safety, tolerability, and pharmacokinetics of JNJ-1802, a Pan-serotype dengue direct antiviral small molecule, in a phase 1, double-blind, randomized, dose-escalation study in healthy volunteers. Clin Infect Dis; 2023;2023(77):857\u2013865.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_3_65_1","unstructured":"Janssen Research & Development LLC. A Phase 2 randomized double-blind placebo-controlled double-dummy multicenter trial assessing the efficacy and safety of two dose regimens of JNJ-64281802 for the prevention of dengue infection. ClinicalTrials.gov 2025. [accessed 2025 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05201794"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2500179"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52819-z"},{"key":"e_1_3_3_68_1","unstructured":"Johnson & Johnson to Discontinue Phase 2 Field Study Evaluating Investigational Antiviral for the Prevention of Dengue. JNJ.com. 2024. [accessed 2025 Nov 13]. Available from: https:\/\/www.jnj.com\/media-center\/press-releases\/johnson-johnson-to-discontinue-phase-2-field-study-evaluating-investigational-antiviral-for-the-prevention-of-dengue."},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb2181"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2426922122"},{"key":"e_1_3_3_71_1","unstructured":"Novartis Pharmaceuticals. A Randomized Participant- and Investigator-blinded Placebo-controlled Parallel Group Study to Assess the Efficacy Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever. clinicaltrials.gov 2025. [accessed 2025 Nov 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06006559"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1303645110"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2015.08.011"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26800-y"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.05.007"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006209"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00030-6"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.11.010"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01123-16"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3058"},{"key":"e_1_3_3_81_1","unstructured":"AbViro LLC. A Phase 1a Double-Blind Placebo-Controlled Single Ascending Dose Study to Determine the Safety and Pharmacokinetics of AV-1 in Healthy Male and Female Adult Subjects. ClinicalTrials.gov 2022. [accessed 2025 Sep 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04273217."},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature18938"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0746-2"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1614805"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003157"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1148850"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2021.01.009"}],"container-title":["Emerging Microbes &amp; Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/22221751.2026.2686471","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/22221751.2026.2686471","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/22221751.2026.2686471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:09:01Z","timestamp":1782104941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/22221751.2026.2686471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/22221751.2026.2686471"],"URL":"https:\/\/doi.org\/10.1080\/22221751.2026.2686471","relation":{},"ISSN":["2222-1751"],"issn-type":[{"value":"2222-1751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=temi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=temi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2686471"}}